Key Disruptors in The Multiple Myeloma Landscape: 2020 and Beyond
Accelerated innovation in drug design and development is providing diverse treatment options for cancer patients, including hematological... In DRG Blog/ April, 2020 ASCO 2019: What's Noteworthy in the CAR T-Cells Corner?
CAR T-cell therapies continue their progress to change cancer treatment paradigms. CAR T Cells and solid tumors Targeting solid tumors with CAR T... In DRG Blog/ June, 2019 What is the U.S. Medical Community's Perception About CAR T-cell Therapies?
In our primary research analysis, we observed positive sentiments in the medical community towards CAR T-cell therapies. Interviewed experts state... In DRG Blog/ July, 2018 ESMO 2017: A Spotlight on Pancreatic Cancer
Each year, the ESMO annual congress delivers the promise of bringing cancer researchers, clinicians and healthcare professionals together for... In DRG Blog/ September, 2017 Immunotherapy and Pancreatic Cancer: The Game of Hide-and-Seek
Pancreatic cancer, recognized as an orphan disease, accounts for just 3% of all new cases of cancers, but is the third leading cause of all cancer-... In DRG Blog, Drug Watch/ June, 2017 Hot Topics at ASCO 2017 – Part 1
Every year ASCO is a highlight in our calendar, where vast amounts of clinical data are unveiled, presented, and discussed. This year is no... In DRG Blog, Drug Watch/ May, 2017